RSLS - Johnson & Johnson sees GLP-1 impact on weight loss surgeries
2023-10-17 12:08:30 ET
More on Johnson & Johnson
- Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy
- Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out
- Johnson & Johnson: The Bull Case Can No Longer Be Ignored
- 5 stocks to watch on Tuesday: J&J, Bank of America, United Airlines and more
- Johnson & Johnson powers to Q3 beat as pharma outperforms
For further details see:
Johnson & Johnson sees GLP-1 impact on weight loss surgeries